Historical record - last NADAC effective date: 8/23/2023
Product Information
LETROZOLE 2.5 MG TABLET is a generic product labeled by Yiling Pharmaceutical Inc., priced at $0.1203 per EA under NDC 69117000401. Its NADAC has been published 185 times since Feb 12, 2020.
FDA first approved this application on Nov 14, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Yiling Pharmaceutical Inc.NDC
69117000401
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/23/2023
Active Ingredients
LETROZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA205869FDA Approved
11/14/2018
TE Code
AB
On Market Since
9/5/2019
Pharmacological Classes
Price Statistics
The NADAC for LETROZOLE 2.5 MG TABLET has been published 185 times since Feb 12, 2020, and over the history we have for it it has declined 12.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1203 per EA |
|---|---|
| All-time high | $0.1485 (Sep 16, 2020) |
| All-time low | $0.1009 (Jun 21, 2023) |
| Median price | $0.1406 |
| Average price | $0.1336 |
| Largest weekly change | +28.5% (Jan 18, 2023) |
| Weeks tracked | 185 |
| Tracking since | Feb 12, 2020 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-15.1%
All
-12.7%
Last surveyed Aug 23, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Yiling Pharmaceutical Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Letrozole Tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LETROZOLE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LETROZOLE 2.5 MG TABLET, manufactured by Yiling Pharmaceutical Inc., is $0.1203 per EA (NDC 69117000401), effective Aug 23, 2023.
How has the price of LETROZOLE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LETROZOLE 2.5 MG TABLET has declined 12.7%. It has been tracked across 185 weekly CMS publications since Feb 12, 2020.
What are the highest and lowest recorded NADAC prices for LETROZOLE 2.5 MG TABLET?
Since Feb 12, 2020, the NADAC for LETROZOLE 2.5 MG TABLET has ranged from a low of $0.1009 (Jun 21, 2023) to a high of $0.1485 (Sep 16, 2020), with a median of $0.1406 per EA.
Are there cheaper alternatives to LETROZOLE 2.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LETROZOLE 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LETROZOLE 2.5 MG TABLET?
LETROZOLE 2.5 MG TABLET (NDC 69117000401) is labeled by Yiling Pharmaceutical Inc., and CMS classifies it as a generic product.